Menu
Search
|

Menu

Close
X

Aclaris Therapeutics Inc ACRS.OQ (NASDAQ Stock Exchange Global Select Market)

20.48 USD
+0.05 (+0.24%)
As of 1:30 AM IST
chart
Previous Close 20.43
Open 20.40
Volume 49,075
3m Avg Volume 92,950
Today’s High 20.51
Today’s Low 20.19
52 Week High 30.06
52 Week Low 16.24
Shares Outstanding (mil) 30.00
Market Capitalization (mil) 828.20
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.29 Mean rating from 7 analysts

KEY STATS

Revenue (mm, USD)
FY18
1
FY17
2
FY16
0
FY15
0
EPS (USD)
FY18
-0.979
FY17
-2.473
FY16
-2.259
FY15
-3.951
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.76
Price to Sales (TTM)
vs sector
--
5.73
Price to Book (MRQ)
vs sector
4.39
5.47
Price to Cash Flow (TTM)
vs sector
--
23.29
Total Debt to Equity (MRQ)
vs sector
0.00
16.84
LT Debt to Equity (MRQ)
vs sector
0.00
12.51
Return on Investment (TTM)
vs sector
-38.27
14.61
Return on Equity (TTM)
vs sector
-38.37
16.34

EXECUTIVE LEADERSHIP

Stephen Tullman
Chairman of the Board, Since 2012
Salary: --
Bonus: --
Neal Walker
President, Chief Executive Officer, Director, Since 2012
Salary: $420,000.00
Bonus: --
Frank Ruffo
Chief Financial Officer, Secretary, Since 2012
Salary: --
Bonus: --
Christopher Powala
Chief Operating Officer, Since 2012
Salary: $345,000.00
Bonus: --
Stuart Shanler
Chief Scientific Officer, Since 2012
Salary: $283,250.00
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

640 Lee Rd Ste 200
WAYNE   PA   19087-5636

Phone: +1484.3247933

Aclaris Therapeutics, Inc. is a dermatologist-led, biopharmaceutical company. The Company is focused on identifying, developing and commercializing differentiated drugs for the treatment of dermatological indications. The Company is also focused on the discovery and development of kinase inhibitors to treat inflammatory and immunological disorders and cancer. The Company’s drug discovery platform KINect technology is a kinase-focused drug discovery engine utilizing computational chemistry to integrate proprietary compound collections and highly experienced biologists and medicinal chemists to identify and advance potential candidates into preclinical and clinical development.

SPONSORED STORIES